Anteris Technologies Global Corp. Prices U.S. IPO at $6.00 Per Share

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of DurAVR® THV for treating severe aortic stenosis. This allocation will accelerate the timeline for DurAVR® THV's commercialization and potentially capture a significant share in the growing transcatheter heart valve market.

The pricing of 14.8 million shares at $6.00 per share raised $88.8 million, indicating a healthy appetite for the offering despite the discount from the proposed reference price of $6.78. The underwriters' 30-day option to purchase an additional 2.22 million shares also reflects a cautious approach to demand, allowing for flexibility in case of increased investor interest.

Anteris Technologies Global Corp. (ATGC) has priced its U.S. initial public offering (IPO) at $6.00 per share, raising $88.8 million. The company plans to use the net proceeds primarily for the ongoing development of its DurAVR® transcatheter heart valve (DurAVR® THV) and the preparation and enrollment of a randomized global pivotal study of Dur